Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP)

Matthew C. Franklin, Saloumeh Kadkhodayan, Heidi Ackerly, Daniela Alexandru, Mark D Distefano, Linda O. Elliott, John A. Flygare, Grace Mausisa, David C. Okawa, Danny Ong, Domagoj Vucic, Kurt Deshayes, Wayne J. Fairbrother

Research output: Contribution to journalArticlepeer-review

80 Scopus citations

Abstract

Melanoma inhibitor of apoptosis (ML-IAP) is a potent anti-apoptotic protein that is upregulated in a number of melanoma cell lines but not expressed in most normal adult tissues. Overexpression of IAP proteins, such as ML-IAP or the ubiquitously expressed X-chromosome-linked IAP (XIAP), in human cancers has been shown to suppress apoptosis induced by a variety of stimuli. Peptides based on the processed N-terminus of Smac/DIABLO can negate the ability of overexpressed ML-IAP or XIAP to suppress drug-induced apoptosis. Such peptides have been demonstrated to bind to the single baculovirus IAP repeat (BIR) of ML-IAP and the third BIR of XIAP with similar high affinities (∼0.5 μM). Herein, we use phage-display of naive peptide libraries and synthetic peptides to investigate the peptide-binding properties of ML-IAP-BIR and XIAP-BIR3. X-ray crystal structures of ML-IAP-BIR in complex with Smac- and phage-derived peptides, together with peptide structure- activity-relationship data, indicate that the peptides can be modified to provide increased binding affinity and selectivity for ML-IAP-BIR relative to XIAP-BIR3. For instance, substitution of Pro3′ in the Smac-based peptide (AVPIAQKSE) with (2S,3S)-3-methylpyrrolidine-2-carboxylic acid [(3S)-methyl-proline] results in a peptide with 7-fold greater affinity for ML-IAP-BIR and about 100-fold specificity for ML-IAP-BIR relative to XIAP-BIR3.

Original languageEnglish (US)
Pages (from-to)8223-8231
Number of pages9
JournalBiochemistry
Volume42
Issue number27
DOIs
StatePublished - Jul 15 2003

Fingerprint

Dive into the research topics of 'Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP)'. Together they form a unique fingerprint.

Cite this